



BIODIEM LTD
ABN 20 096 845 993

Level 10, South Tower,
459 Collins Street,
Melbourne, Victoria, 3000
Australia

Phone: +61 3 9613 4100
Fax: +61 3 9613 4111
Email: info@biodiem.com
Web: www.biodiem.com

ASX Announcement

Date: 20 August 2008

BioDiem announces development of a protocol for commercial-scale manufacture of BDM-E

Melbourne, Wednesday 20 August 2008: Australian pharmaceutical development company BioDiem (ASX:BDM) and Genzyme Pharmaceuticals' custom peptide manufacturing group based in Liestal, Switzerland announced today that they have successfully developed a solution phase/recrystallization protocol suitable for commercial scale manufacture of BDM-E.

Genzyme Pharmaceuticals is a GMP certified custom manufacturer with a specialization in peptide synthesis, lipid and small molecule API manufacture. Dr. Marc New, Senior Director, Commercial Development at Genzyme Pharmaceuticals, Liestal said, "We are pleased to be working with BioDiem to successfully develop long term, sustainable, cost effective methodologies for large scale manufacture of small peptides".

"Producing a cost effective, scalable GMP protocol for the manufacture of drug candidates is an often overlooked component of commercial drug development by early stage biotechnology companies" stated Chief Executive Officer, Dr. Andrew O'Brien. "A low cost manufacturing protocol that meets the requirements of international regulators is a key element in successfully bringing a commercially viable product to market, either "in-house" and/or in partnership. This outcome allows BioDiem increased flexibility in defining the appropriate dosing regimen for BDM-E when entering the clinic".

Chairman Mr Hugh Morgan AC said, "Whilst BioDiem continues to complete pharmacological studies associated with BDM-E, this result favourably positions the company for achieving its goal of continuing product development with a clear eye on international registration".

Genzyme Pharmaceuticals has been engaged to manufacture BDM-E as BioDiem works towards completing pre-clinical product development and prepares for the clinical development of BDM-E.

About BioDiem Ltd

BioDiem is an Australian listed company, based in Melbourne, with an international focus on finding, adding value to and commercialising world-class research for vaccines, infectious diseases and other therapeutic areas. The company takes a cost-efficient approach to drug development by project managing a portfolio of new products through collaborations with academic centres of excellence, contract research organizations and partnerships with international pharmaceutical companies. For additional information, please visit www.biodiem.com

Further information

Andrew P. O'Brien, Ph.D.
Chief Executive Officer
BioDiem Ltd
Ph: +61 3 9613 4100
Mob: +61 438 550 893